A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

NCT07668414 · tracked via the Priya Life Science USA tracker

Sponsor

Novo Nordisk A/S

Phase

Phase 3

Started

2026-09-22

Last updated

2026-08-25

Condition(s) studied

OverweightObesity

Investigational drug(s) / intervention(s)

ZenagamtideSemaglutidePlacebo (matched to semaglutide)Placebo (matched to zenagamtide)

Zenagamtide: Zenagamtide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Semaglutide: Semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Placebo (matched to semaglutide): Placebo matched to semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Placebo (matched to zenagamtide): Placebo matched to zenagamtide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Study summary

The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.

Primary outcome measure(s)

Relative change in body weight — From week 0 to week 84
Measured as percentage (%) change in body weight.

Trial sites (43)

Facility	City	Region
First Valley Medical Group	Lancaster	California
Desert Oasis Healthcare	Palm Springs	California
Western University of Health Sciences	Pomona	California
Artemis Insitute for Clin Res	San Diego	California
Med Home Development Grp	Washington D.C.	District of Columbia
Encore Medical Research LLC	Hollywood	Florida
NextPhase Research	Hollywood	Florida
Jacksonville Ctr Clin Res	Jacksonville	Florida
PharmaDev Clinical Research Institute LLC	Miami	Florida
South Broward Research LLC	Miramar	Florida
Essence MD Research	Naples	Florida
Florida Inst For Clin Res LLC	Orlando	Florida
Oviedo Medical Research, LLC	Oviedo	Florida
Palm Beach Research Center	West Palm Beach	Florida
Encore Medical Research of Weston	Weston	Florida
Conquest Research	Atlanta	Georgia
Eastside Bariatric and Gen Surg	Snellville	Georgia
Chicago Research Center, Inc	Chicago	Illinois
Endeavor Health	Skokie	Illinois
Midwest Inst For Clin Res	Indianapolis	Indiana
Southern Clin Research	Zachary	Louisiana
Amicis Centers of Clinical Research	St Louis	Missouri
Ichor Research	Syracuse	New York
Southgate Medical Group, LLP	West Seneca	New York
Lillestol Research LLC	Fargo	North Dakota
Geisinger Clinic	Danville	Pennsylvania
Medical University Of South Carolina	Charleston	South Carolina
Hillcrest Clinical Research	Simpsonville	South Carolina
Spartanburg Medical Research	Spartanburg	South Carolina
Amarillo Med Spec LLP	Amarillo	Texas
Texas Diabetes & Endocrinology	Austin	Texas
Pinnacle Clinical Research	Brownsville	Texas
Osvaldo A. Brusco MD	Corpus Christi	Texas
UT Southwestern Med Center	Dallas	Texas
Epic Medical Research	DeSoto	Texas
Houston Research Institute	Houston	Texas
The Endocrine Center	Houston	Texas
Sleep Therapy Research Center	San Antonio	Texas
Olympus Clinical Research	Sugar Land	Texas
National Clin Res Inc.	Richmond	Virginia

+ 3 more sites — see the full list on the official registry below.

On this site

📄 Ozempic (semaglutide) drug profile →

More Novo Nordisk A/S trials in the USA

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide Active, not recruiting

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack Active, not recruiting

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight Active, not recruiting

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow Active, not recruiting

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis Active, not recruiting

Other trials for the same condition

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide Active, not recruiting

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity Recruiting

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Recruiting

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight Active, not recruiting

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07668414 on ClinicalTrials.gov ↗ ← All trials in the USA